Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Sathianathen NJ, Dahm P, Brown SJ, Oestreich M, Gupta S, Konety BR, Kunath F (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Cochrane Database of Systematic Reviews Cochrane Collaboration

Book Volume: 2019

Article Number: CD013245

Journal Issue: 1

DOI: 10.1002/14651858.CD013245

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.

Authors with CRIS profile

Frank Kunath Urologische Klinik

Additional Organisation(s)

Urologische Klinik

Involved external institutions

Va Midwest Health Care Network US United States (USA) (US) University of Minnesota (UMN) US United States (USA) (US)

How to cite

APA:

Sathianathen, N.J., Dahm, P., Brown, S.J., Oestreich, M., Gupta, S., Konety, B.R., & Kunath, F. (2019). Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. Cochrane Database of Systematic Reviews, 2019(1). https://doi.org/10.1002/14651858.CD013245

MLA:

Sathianathen, Niranjan J., et al. "Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer." Cochrane Database of Systematic Reviews 2019.1 (2019).

BibTeX: Download